Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Influenza Patients at High Risk of Complications

Baloxavir marboxil, a prodrug of cap-dependent endonuclease inhibitor baloxavir acid, reduces the time to improvement of influenza symptoms in patients infected with type A or B influenza virus. To characterize its pharmacokinetics, a population pharmacokinetic model for baloxavir acid was developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Koshimichi, Hiroki, Retout, Sylvie, Cosson, Valerie, Duval, Vincent, De Buck, Stefan, Tsuda, Yoshiyuki, Ishibashi, Toru, Wajima, Toshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318003/
https://www.ncbi.nlm.nih.gov/pubmed/32312784
http://dx.doi.org/10.1128/AAC.00119-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318003/
https://www.ncbi.nlm.nih.gov/pubmed/32312784
http://dx.doi.org/10.1128/AAC.00119-20

Ejemplares similares